@article{769c16f3a9d24305904d117e5926eae7,
title = "Joint-label fusion brain atlases for dementia research in Down syndrome",
abstract = "Research suggests a link between Alzheimer's Disease in Down Syndrome (DS) and the overproduction of amyloid plaques. Using Positron Emission Tomography (PET) we can assess the in-vivo regional amyloid load using several available ligands. To measure amyloid distributions in specific brain regions, a brain atlas is used. A popular method of creating a brain atlas is to segment a participant's structural Magnetic Resonance Imaging (MRI) scan. Acquiring an MRI is often challenging in intellectually-imparied populations because of contraindications or data exclusion due to significant motion artifacts or incomplete sequences related to general discomfort. When an MRI cannot be acquired, it is typically replaced with a standardized brain atlas derived from neurotypical populations (i.e. healthy individuals without DS) which may be inappropriate for use in DS. In this project, we create a series of disease and diagnosis-specific (cognitively stable (CS-DS), mild cognitive impairment (MCI-DS), and dementia (DEM-DS)) probabilistic group atlases of participants with DS and evaluate their accuracy of quantifying regional amyloid load compared to the individually-based MRI segmentations. Further, we compare the diagnostic-specific atlases with a probabilistic atlas constructed from similar-aged cognitively-stable neurotypical participants. We hypothesized that regional PET signals will best match the individually-based MRI segmentations by using DS group atlases that aligns with a participant's disorder and disease status (e.g. DS and MCI-DS). Our results vary by brain region but generally show that using a disorder-specific atlas in DS better matches the individually-based MRI segmentations than using an atlas constructed from cognitively-stable neurotypical participants. We found no additional benefit of using diagnose-specific atlases matching disease status. All atlases are made publicly available for the research community. Highlight: Down syndrome (DS) joint-label-fusion atlases provide accurate positron emission tomography (PET) amyloid measurements. A disorder-specific DS atlas is better than a neurotypical atlas for PET quantification. It is not necessary to use a disease-state–specific atlas for quantification in aged DS. Dorsal striatum results vary, possibly due to this region and dementia progression.",
keywords = "Alzheimer's disease, Down syndrome, amyloid, dementia, group atlas, joint label fusion, neurotypical",
author = "{for the Alzheimer's Biomarkers Consortium} and Nazek Queder and Phelan, {Michael J.} and Lisa Taylor and Nicholas Tustison and Eric Doran and Christy Hom and Dana Nguyen and Florence Lai and Margaret Pulsifer and Julie Price and Kreisl, {William C.} and Rosas, {Herminia D.} and Sharon Krinsky-McHale and Brickman, {Adam M.} and Yassa, {Michael A.} and Nicole Schupf and Wayne Silverman and Lott, {Ira T.} and Elizabeth Head and Mark Mapstone and Keator, {David B.} and Aizenstein, {Howard J.} and Ances, {Beau M.} and Andrews, {Howard F.} and Karen Bell and Birn, {Rasmus M.} and Brickman, {Adam M.} and Peter Bulova and Amrita Cheema and Kewei Chen and Christian, {Bradley T.} and Isabel Clare and Lorraine Clark and Cohen, {Ann D.} and Constantino, {John N.} and Doran, {Eric W.} and Anne Fagan and Eleanor Feingold and Foroud, {Tatiana M.} and Handen, {Benjamin L.} and Hartley, {Sigan L.} and Elizabeth Head and Rachel Henson and Lawrence Honig and Ikonomovic, {Milos D.} and Johnson, {Sterling C.} and Courtney Jordan and Kamboh, {M. Ilyas} and Sid O'Bryant and Melissa Petersen",
note = "Funding Information: The preparation of this manuscript was made possible from data obtained by the Alzheimer's Disease in Down Syndrome (ADDS) component of the Alzheimer's Biomarkers Consortium–Down Syndrome (ABC‐DS), a longitudinal study of Alzheimer disease biomarkers in adults with Down syndrome is supported by grants from the National Institute on Aging (NIA; U01AG051412‐01 Schupf, Lott, Silverman) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The Co‐Principal Investigators of the ADDS component of the ABC‐DS program are Nicole Schupf, PhD, Dr. PH. (Columbia University), Ira Lott, MD, and Wayne Silverman, PhD (UC Irvine). Co‐Principal Investigators of the NiAD ABC‐DS component are Benjamin Handen, PhD and William Klunk, MD, PhD (University of Pittsburgh), and Bradley Christian, PhD (University of Wisconsin‐Madison). Neurotypical data were collected under the Neuroimaging biomarkers for cognitive decline in elderly with amyloid pathology (NIA) grant from the National Institute on Aging (R01AG053555 Yassa, Gillen). The atlases and data processing scripts were made available using the recommendations for FAIR data, tools, and techniques from ReproNim: A Center for Reproducible Neuroimaging Computation supported by a grant from the National Institute of Biomedical Imaging and Bioengineering (P41 EB019936; Kennedy). The Alzheimer's Biomarkers Consortium–Down Syndrome (ABC‐DS) is funded by the National Institute on Aging and the National Institute for Child Health and Human Development (U01 AG051406 and U01 AG051412). The work contained in this publication was also supported through the following National Institutes of Health Programs: The Alzheimer's Disease Research Centers Program (P50 AG008702, P30 AG062421, P50 AG16537, P50 AG005133, P50 AG005681, and P30 AG062715), the Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers Program (U54 HD090256 and U54 HD087011), the National Centers for Advancing Translational Sciences (UL1 TR001873, UL1 TR002373, UL1 TR001414, UL1 TR001857, UL1 TR002345), the National Centralized Repository for Alzheimer Disease and Related Dementias (U24 AG21886), and DS‐Connect{\textregistered} (The Down Syndrome Registry) supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The authors thank the ABC‐DS study participants (adults with Down syndrome and their siblings), their families and care providers, and the ABC‐DS research and support staff for their invaluable contributions to this study. The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH. Funding Information: The preparation of this manuscript was made possible from data obtained by the Alzheimer's Disease in Down Syndrome (ADDS) component of the Alzheimer's Biomarkers Consortium–Down Syndrome (ABC-DS), a longitudinal study of Alzheimer disease biomarkers in adults with Down syndrome is supported by grants from the National Institute on Aging (NIA; U01AG051412-01 Schupf, Lott, Silverman) and Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The Co-Principal Investigators of the ADDS component of the ABC-DS program are Nicole Schupf, PhD, Dr. PH. (Columbia University), Ira Lott, MD, and Wayne Silverman, PhD (UC Irvine). Co-Principal Investigators of the NiAD ABC-DS component are Benjamin Handen, PhD and William Klunk, MD, PhD (University of Pittsburgh), and Bradley Christian, PhD (University of Wisconsin-Madison). Neurotypical data were collected under the Neuroimaging biomarkers for cognitive decline in elderly with amyloid pathology (NIA) grant from the National Institute on Aging (R01AG053555 Yassa, Gillen). The atlases and data processing scripts were made available using the recommendations for FAIR data, tools, and techniques from ReproNim: A Center for Reproducible Neuroimaging Computation supported by a grant from the National Institute of Biomedical Imaging and Bioengineering (P41 EB019936; Kennedy). The Alzheimer's Biomarkers Consortium–Down Syndrome (ABC-DS) is funded by the National Institute on Aging and the National Institute for Child Health and Human Development (U01 AG051406 and U01 AG051412). The work contained in this publication was also supported through the following National Institutes of Health Programs: The Alzheimer's Disease Research Centers Program (P50 AG008702, P30 AG062421, P50 AG16537, P50 AG005133, P50 AG005681, and P30 AG062715), the Eunice Kennedy Shriver Intellectual and Developmental Disabilities Research Centers Program (U54 HD090256 and U54 HD087011), the National Centers for Advancing Translational Sciences (UL1 TR001873, UL1 TR002373, UL1 TR001414, UL1 TR001857, UL1 TR002345), the National Centralized Repository for Alzheimer Disease and Related Dementias (U24 AG21886), and DS-Connect{\textregistered} (The Down Syndrome Registry) supported by the Eunice Kennedy Shriver National Institute of Child Health and Human Development. The authors thank the ABC-DS study participants (adults with Down syndrome and their siblings), their families and care providers, and the ABC-DS research and support staff for their invaluable contributions to this study. The content is the sole responsibility of the authors and does not necessarily represent the official views of the NIH. Publisher Copyright: {\textcopyright} 2022 The Authors. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring published by Wiley Periodicals, LLC on behalf of Alzheimer's Association.",
year = "2022",
month = jan,
day = "1",
doi = "10.1002/dad2.12324",
language = "English",
volume = "14",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "1",
}